Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Nitisinone is a medication, effectively used for the treatment and maintainence of alkaptonuria, an autosomal recessive disease. Its mode of action involves the inhibition of second enzyme in the tyrosine pathway, 4-hydroxyphenylpyruvate dioxygenase that produces HGA from 4-hydroxyphenylpyruvate.
Synonyms: Nitisinone; 2-(2-Nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; 2-[2-Nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione; NTBC; Nitisone; SC 0735
Molecular Formula: C14H10F3NO5
Molecular Weight: 329.23
Linear Structural Formula: C14H10F3NO5
MDL Number: MFCD01752192
Application: These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Biochem Physiol Actions: Nitisinone is a competitive inhibitor that reversibly inhibits 4-Hydroxyphenylpyruvate oxidase (dioxygenase). Nitisinone is used in the treatment of hereditary tyrosinemia type 1, where it blocks the degradation of tyrosine into harmful substances.
Other Notes: This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.